Clinical Trials Logo

Clinical Trial Summary

The principal objective is to evaluate a cure rate and number of adverse events of with confirmed multidrug-resistant tuberculosis patient treated with a 9months regimen.


Clinical Trial Description

Study participants will be followed up, under existing protocol derived from a study protocol developed by the "Union internationale contre les maladies respiratoires" and carried out already in 9 Africans countries. Participants will be hospitalised for at least four month, period which they will be given treatments, assessed for adverse events, monitored for TB-MR strains using culture techniques, at the monthly basis. If patients found with negative sputum culture at month four they will be dischrged from the hospital, and then treated four an additional five montns and then follow up, clinically and biologically for an additional six months before being declared as cured. ;


Study Design


Related Conditions & MeSH terms

  • Multi-drug Resistant Tuberculosis
  • Tuberculosis
  • Tuberculosis, Multidrug-Resistant

NCT number NCT03057756
Study type Observational [Patient Registry]
Source Centre de Recherche Médicale de Lambaréné
Contact Ayola A Adegnika, MD, PhD
Phone +24107406464
Email aadegnika@cermel.org
Status Recruiting
Phase
Start date September 11, 2015
Completion date July 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT04207112 - Economic Evaluation of New MDR TB Regimens Phase 2/Phase 3
Completed NCT03000517 - PK of Levofloxacin in MDR-TB Patients N/A
Completed NCT03470233 - Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB
Completed NCT03830671 - The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB Phase 4
Withdrawn NCT01600963 - A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis Phase 3
Recruiting NCT03575299 - Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic γδT Cells Phase 1
Recruiting NCT03827811 - Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis
Completed NCT04342598 - Case Control Study of Vitamin D Status and Adult Multidrug-resistant Pulmonary Tuberculosis in Maharashtra, India
Completed NCT04309656 - A Study in Two Panels of Healthy Adult Participants to Assess Single-Dose Immediate-Release and Single-Dose Dispersible Formulations of Pretomanid Phase 1
Completed NCT03822156 - Clinical Analysis of the Patients With Cavitary Pulmonary TB and Endobronchial TB in the PPM-UUH Cohort
Completed NCT00425113 - Metronidazole for Pulmonary Tuberculosis (South Korea) Phase 2
Active, not recruiting NCT04081077 - PRACTECAL-PKPD Sub Study Phase 2/Phase 3
Recruiting NCT04397536 - New Genomic Techniques and Management of Multidrug-resistant Tuberculosis
Completed NCT00664313 - TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB Phase 1/Phase 2
Completed NCT00691392 - Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB) Phase 1/Phase 2